148 related articles for article (PubMed ID: 27502712)
1. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P; Gutzmer R; Ascierto PA; Maio M; Grob JJ; Murawa P; Dreno B; Ross M; Weber J; Hauschild A; Rutkowski P; Testori A; Levchenko E; Enk A; Misery L; Vanden Abeele C; Vojtek I; Peeters O; Brichard VG; Therasse P
Ann Oncol; 2016 Oct; 27(10):1947-53. PubMed ID: 27502712
[TBL] [Abstract][Full Text] [Related]
2. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract][Full Text] [Related]
3. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
McQuade JL; Homsi J; Torres-Cabala CA; Bassett R; Popuri RM; James ML; Vence LM; Hwu WJ
BMC Cancer; 2018 Dec; 18(1):1274. PubMed ID: 30567529
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
6. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
Pujol JL; Vansteenkiste JF; De Pas TM; Atanackovic D; Reck M; Thomeer M; Douillard JY; Fasola G; Potter V; Taylor P; Bosquée L; Scheubel R; Jarnjak S; Debois M; de Sousa Alves P; Louahed J; Brichard VG; Lehmann FF
J Thorac Oncol; 2015 Oct; 10(10):1458-67. PubMed ID: 26309191
[TBL] [Abstract][Full Text] [Related]
8. Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.
Baurain JF; Robert C; Mortier L; Neyns B; Grange F; Lebbe C; Ulloa-Montoya F; De Sousa Alves PM; Gillet M; Louahed J; Jarnjak S; Lehmann FF
ESMO Open; 2018; 3(5):e000384. PubMed ID: 30094070
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
Grob JJ; Mortier L; D'Hondt L; Grange F; Baurain JF; Dréno B; Lebbe C; Robert C; Dompmartin A; Neyns B; Gillet M; Louahed J; Jarnjak S; Lehmann FF
ESMO Open; 2017; 2(5):e000203. PubMed ID: 29177094
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
[TBL] [Abstract][Full Text] [Related]
11. MAGE A3 antigen-specific cancer immunotherapeutic.
Peled N; Oton AB; Hirsch FR; Bunn P
Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
[TBL] [Abstract][Full Text] [Related]
12. A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.
Duperret EK; Liu S; Paik M; Trautz A; Stoltz R; Liu X; Ze K; Perales-Puchalt A; Reed C; Yan J; Xu X; Weiner DB
Clin Cancer Res; 2018 Dec; 24(23):6015-6027. PubMed ID: 30262507
[TBL] [Abstract][Full Text] [Related]
13. A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Chianese-Bullock KA; Mauldin IS; Smith KT; Deacon DH; Varhegyi NE; Donnelly SB; Reed CM; Scott K; Galeassi NV; Grosh WW
Cancer Immunol Immunother; 2016 Jan; 65(1):25-36. PubMed ID: 26581199
[TBL] [Abstract][Full Text] [Related]
14. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys.
Destexhe E; Grosdidier E; Baudson N; Forster R; Gerard C; Garçon N; Segal L
J Appl Toxicol; 2015 Jul; 35(7):717-28. PubMed ID: 25219328
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
17. MAGE-A3: an immunogenic target used in clinical practice.
Esfandiary A; Ghafouri-Fard S
Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.
Fontana R; Bregni M; Cipponi A; Raccosta L; Rainelli C; Maggioni D; Lunghi F; Ciceri F; Mukenge S; Doglioni C; Colau D; Coulie PG; Bordignon C; Traversari C; Russo V
Blood; 2009 Feb; 113(8):1651-60. PubMed ID: 19074732
[TBL] [Abstract][Full Text] [Related]
19. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
Morgan RA; Chinnasamy N; Abate-Daga D; Gros A; Robbins PF; Zheng Z; Dudley ME; Feldman SA; Yang JC; Sherry RM; Phan GQ; Hughes MS; Kammula US; Miller AD; Hessman CJ; Stewart AA; Restifo NP; Quezado MM; Alimchandani M; Rosenberg AZ; Nath A; Wang T; Bielekova B; Wuest SC; Akula N; McMahon FJ; Wilde S; Mosetter B; Schendel DJ; Laurencot CM; Rosenberg SA
J Immunother; 2013 Feb; 36(2):133-51. PubMed ID: 23377668
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
Russo V; Pilla L; Lunghi F; Crocchiolo R; Greco R; Ciceri F; Maggioni D; Fontana R; Mukenge S; Rivoltini L; Rigamonti G; Mercuri SR; Nicoletti R; Maschio AD; Gianolli L; Fazio F; Marchianò A; Florio AD; Maio M; Salomoni M; Gallo-Stampino C; Fiacco MD; Lambiase A; Coulie PG; Patuzzo R; Parmiani G; Traversari C; Bordignon C; Santinami M; Bregni M
Int J Cancer; 2013 Jun; 132(11):2557-66. PubMed ID: 23151995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
